Literature DB >> 28835721

Immunotherapy: Searching in the immune checkpoint black box.

M Teresa Villanueva1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28835721     DOI： 10.1038/nrc.2017.75

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962
  1 in total
  2 in total

Review 1.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.

Authors:  Mengling Wu; Qianrui Huang; Yao Xie; Xuyi Wu; Hongbo Ma; Yiwen Zhang; Yong Xia
Journal:  J Hematol Oncol       Date:  2022-03-12       Impact factor: 17.388

2.  PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.

Authors:  Verena Rolfes; Christian Idel; Ralph Pries; Bernardo S Franklin; Barbara Wollenberg; Kirstin Plötze-Martin; Jens Habermann; Timo Gemoll; Sabine Bohnet; Eicke Latz; Julika Ribbat-Idel
Journal:  Oncotarget       Date:  2018-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.